Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients
Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model o...
Gespeichert in:
| Veröffentlicht in: | Blood 2011-07, Vol.118 (3), p.675-678 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 678 |
|---|---|
| container_issue | 3 |
| container_start_page | 675 |
| container_title | Blood |
| container_volume | 118 |
| creator | Magrangeas, Florence Avet-Loiseau, Hervé Munshi, Nikhil C. Minvielle, Stéphane |
| description | Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model of cancer evolution based on ongoing genomic instability mechanism may apply to development of most MM cases. However, in a small fraction of newly diagnosed MM who relapse quickly and finally die within 2 years, the gradual model appears to be untenable. Analysis of high resolution copy number profiles obtained using single nucleotide polymorphism array data from 764 newly diagnosed MM identified large numbers of genomic rearrangements with the hallmarks of chromothripsis in 1.3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution. |
| doi_str_mv | 10.1182/blood-2011-03-344069 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3142904</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120447482</els_id><sourcerecordid>878823124</sourcerecordid><originalsourceid>FETCH-LOGICAL-c558t-7936affefa344915f10675d67b48f927bca162b4256904e68ab48f5b2c88923e3</originalsourceid><addsrcrecordid>eNp9UU2P0zAQtRCILQv_ACFfEKeAv5I4FyRUAbvSSlzgbE2ccWrkxMVOi_rvcWjZhQunObyPeTOPkJecveVci3d9iHGoBOO8YrKSSrGme0Q2vBa6Ykywx2TDGGsq1bX8ijzL-TtjXElRPyVXgjdCK9ZuiNvuUpziskt-n32mfsB58c5jpkATJKQwDxTGMWHO_oh0hZcThSnOI53xZzjRwcM4x4wDnQ5h8fuAdDphiBPQPSy-KPJz8sRByPjiMq_Jt08fv25vqrsvn2-3H-4qW9d6qdpONuAcOij3dLx2nDVtPTRtr7TrRNtbKMl7JeqmYwobDStQ98Jq3QmJ8pq8P_vuD_2Egy27EwSzT36CdDIRvPkXmf3OjPFoJFeiWBaDNxeDFH8cMC9m8tliCDBjPGSjW62F5GJlqjPTpphzQne_hTOzNmR-N2TWhgyT5txQkb36O-G96E8lhfD6QoBsIbgEs_X5gadkI-qOPZyK5Z9Hj8lkW35tcfAJ7WKG6P-f5BcEG7I_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>878823124</pqid></control><display><type>article</type><title>Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Magrangeas, Florence ; Avet-Loiseau, Hervé ; Munshi, Nikhil C. ; Minvielle, Stéphane</creator><creatorcontrib>Magrangeas, Florence ; Avet-Loiseau, Hervé ; Munshi, Nikhil C. ; Minvielle, Stéphane</creatorcontrib><description>Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model of cancer evolution based on ongoing genomic instability mechanism may apply to development of most MM cases. However, in a small fraction of newly diagnosed MM who relapse quickly and finally die within 2 years, the gradual model appears to be untenable. Analysis of high resolution copy number profiles obtained using single nucleotide polymorphism array data from 764 newly diagnosed MM identified large numbers of genomic rearrangements with the hallmarks of chromothripsis in 1.3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2011-03-344069</identifier><identifier>PMID: 21628407</identifier><language>eng</language><publisher>Washington, DC: Elsevier Inc</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Chromosome Breakage ; Clinical Trials and Observations ; Gene Dosage - genetics ; Gene Rearrangement - genetics ; Genomic Instability - genetics ; Genomics ; Hematologic and hematopoietic diseases ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunopathology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoid Neoplasia ; Medical sciences ; Middle Aged ; Molecular Sequence Data ; Multiple Myeloma - genetics ; Multiple Myeloma - mortality ; Polymorphism, Single Nucleotide - genetics ; Risk Factors</subject><ispartof>Blood, 2011-07, Vol.118 (3), p.675-678</ispartof><rights>2011 American Society of Hematology</rights><rights>2015 INIST-CNRS</rights><rights>2011 by The American Society of Hematology 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c558t-7936affefa344915f10675d67b48f927bca162b4256904e68ab48f5b2c88923e3</citedby><cites>FETCH-LOGICAL-c558t-7936affefa344915f10675d67b48f927bca162b4256904e68ab48f5b2c88923e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24362590$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21628407$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Magrangeas, Florence</creatorcontrib><creatorcontrib>Avet-Loiseau, Hervé</creatorcontrib><creatorcontrib>Munshi, Nikhil C.</creatorcontrib><creatorcontrib>Minvielle, Stéphane</creatorcontrib><title>Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients</title><title>Blood</title><addtitle>Blood</addtitle><description>Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model of cancer evolution based on ongoing genomic instability mechanism may apply to development of most MM cases. However, in a small fraction of newly diagnosed MM who relapse quickly and finally die within 2 years, the gradual model appears to be untenable. Analysis of high resolution copy number profiles obtained using single nucleotide polymorphism array data from 764 newly diagnosed MM identified large numbers of genomic rearrangements with the hallmarks of chromothripsis in 1.3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Chromosome Breakage</subject><subject>Clinical Trials and Observations</subject><subject>Gene Dosage - genetics</subject><subject>Gene Rearrangement - genetics</subject><subject>Genomic Instability - genetics</subject><subject>Genomics</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoid Neoplasia</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Sequence Data</subject><subject>Multiple Myeloma - genetics</subject><subject>Multiple Myeloma - mortality</subject><subject>Polymorphism, Single Nucleotide - genetics</subject><subject>Risk Factors</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU2P0zAQtRCILQv_ACFfEKeAv5I4FyRUAbvSSlzgbE2ccWrkxMVOi_rvcWjZhQunObyPeTOPkJecveVci3d9iHGoBOO8YrKSSrGme0Q2vBa6Ykywx2TDGGsq1bX8ijzL-TtjXElRPyVXgjdCK9ZuiNvuUpziskt-n32mfsB58c5jpkATJKQwDxTGMWHO_oh0hZcThSnOI53xZzjRwcM4x4wDnQ5h8fuAdDphiBPQPSy-KPJz8sRByPjiMq_Jt08fv25vqrsvn2-3H-4qW9d6qdpONuAcOij3dLx2nDVtPTRtr7TrRNtbKMl7JeqmYwobDStQ98Jq3QmJ8pq8P_vuD_2Egy27EwSzT36CdDIRvPkXmf3OjPFoJFeiWBaDNxeDFH8cMC9m8tliCDBjPGSjW62F5GJlqjPTpphzQne_hTOzNmR-N2TWhgyT5txQkb36O-G96E8lhfD6QoBsIbgEs_X5gadkI-qOPZyK5Z9Hj8lkW35tcfAJ7WKG6P-f5BcEG7I_</recordid><startdate>20110721</startdate><enddate>20110721</enddate><creator>Magrangeas, Florence</creator><creator>Avet-Loiseau, Hervé</creator><creator>Munshi, Nikhil C.</creator><creator>Minvielle, Stéphane</creator><general>Elsevier Inc</general><general>Americain Society of Hematology</general><general>American Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110721</creationdate><title>Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients</title><author>Magrangeas, Florence ; Avet-Loiseau, Hervé ; Munshi, Nikhil C. ; Minvielle, Stéphane</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c558t-7936affefa344915f10675d67b48f927bca162b4256904e68ab48f5b2c88923e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Chromosome Breakage</topic><topic>Clinical Trials and Observations</topic><topic>Gene Dosage - genetics</topic><topic>Gene Rearrangement - genetics</topic><topic>Genomic Instability - genetics</topic><topic>Genomics</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoid Neoplasia</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Sequence Data</topic><topic>Multiple Myeloma - genetics</topic><topic>Multiple Myeloma - mortality</topic><topic>Polymorphism, Single Nucleotide - genetics</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Magrangeas, Florence</creatorcontrib><creatorcontrib>Avet-Loiseau, Hervé</creatorcontrib><creatorcontrib>Munshi, Nikhil C.</creatorcontrib><creatorcontrib>Minvielle, Stéphane</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Magrangeas, Florence</au><au>Avet-Loiseau, Hervé</au><au>Munshi, Nikhil C.</au><au>Minvielle, Stéphane</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2011-07-21</date><risdate>2011</risdate><volume>118</volume><issue>3</issue><spage>675</spage><epage>678</epage><pages>675-678</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Multiple myeloma (MM) develops from a premalignant plasma cell proliferative disorder, and with time can progress to a more aggressive disease in extramedullary locations. The gradually clinical evolution is supported by clonal expansion of cells that acquire genetic lesions over years. This model of cancer evolution based on ongoing genomic instability mechanism may apply to development of most MM cases. However, in a small fraction of newly diagnosed MM who relapse quickly and finally die within 2 years, the gradual model appears to be untenable. Analysis of high resolution copy number profiles obtained using single nucleotide polymorphism array data from 764 newly diagnosed MM identified large numbers of genomic rearrangements with the hallmarks of chromothripsis in 1.3% of samples. Moreover, this catastrophic event confers a poor outcome. Because chromothripsis appears to occur in a single crisis, our results suggest that high-risk MM patients use this novel way of cancer evolution.</abstract><cop>Washington, DC</cop><pub>Elsevier Inc</pub><pmid>21628407</pmid><doi>10.1182/blood-2011-03-344069</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2011-07, Vol.118 (3), p.675-678 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3142904 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Aged Biological and medical sciences Chromosome Breakage Clinical Trials and Observations Gene Dosage - genetics Gene Rearrangement - genetics Genomic Instability - genetics Genomics Hematologic and hematopoietic diseases Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoid Neoplasia Medical sciences Middle Aged Molecular Sequence Data Multiple Myeloma - genetics Multiple Myeloma - mortality Polymorphism, Single Nucleotide - genetics Risk Factors |
| title | Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T12%3A53%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chromothripsis%20identifies%20a%20rare%20and%20aggressive%20entity%20among%20newly%20diagnosed%20multiple%20myeloma%20patients&rft.jtitle=Blood&rft.au=Magrangeas,%20Florence&rft.date=2011-07-21&rft.volume=118&rft.issue=3&rft.spage=675&rft.epage=678&rft.pages=675-678&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2011-03-344069&rft_dat=%3Cproquest_pubme%3E878823124%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=878823124&rft_id=info:pmid/21628407&rft_els_id=S0006497120447482&rfr_iscdi=true |